Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 312.38M P/E - EPS this Y -0.50% Ern Qtrly Grth -
Income -53.47M Forward P/E -5.21 EPS next Y -1.60% 50D Avg Chg 12.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 33.00%
Dividend N/A Price/Book 2.89 EPS next 5Y - 52W High Chg -34.00%
Recommedations 2.20 Quick Ratio 10.92 Shares Outstanding 29.65M 52W Low Chg 189.00%
Insider Own 29.18% ROA -32.46% Shares Float 17M Beta -0.89
Inst Own 38.03% ROE -53.36% Shares Shorted/Prior 2.73M/2.61M Price 10.68
Gross Margin - Profit Margin - Avg. Volume 118,643 Target Price 13.29
Oper. Margin - Earnings Date - Volume 52,517 Change 0.38%
About Immuneering Corporation

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Immuneering Corporation News
03:30 PM Immuneering Recognizes Melanoma Awareness Month
04/09/24 IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
04/03/24 Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03/27/24 Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
03/21/24 Immuneering Director Acquires 7.5% More Stock
03/18/24 Immuneering (IMRX) Plummets 71% in One Week: Here's Why
03/14/24 Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
03/12/24 Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
03/11/24 Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
03/05/24 Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
03/04/24 Immuneering to Participate in the Cowen 44th Annual Health Care Conference
03/03/24 Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results
03/01/24 Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
02/20/24 Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
02/14/24 3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave
02/01/24 Immuneering Announces Participation in February Investor Conferences
01/09/24 With 37% ownership, Immuneering Corporation (NASDAQ:IMRX) has piqued the interest of institutional investors
12/12/23 Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
11/29/23 Here's Why We're Watching Immuneering's (NASDAQ:IMRX) Cash Burn Situation
11/20/23 Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
IMRX Chatroom

User Image biff1 Posted - 5 hours ago

$IMRX Back over $3 soon! Hold on!

User Image tallguy777 Posted - 3 days ago

$IMRX i see green.

User Image InsaneGainz Posted - 3 days ago

$IMRX oh, what have we here

User Image intratio Posted - 4 days ago

The predictive model foretells that the value of this company has a good prognosis for the near future and is poised to gain long-term positive momentum $IMRX

User Image a0Br0 Posted - 4 days ago

$IMRX

User Image biff1 Posted - 4 days ago

$IMRX

User Image FrankieBee Posted - 4 days ago

$IMRX I guess earnings date has changed.

User Image tallguy777 Posted - 4 days ago

$IMRX i see some green.

User Image Bwnuts Posted - 5 days ago

$IMRX same low + higher high and someone supported this through a 200k share dump at 1.38. Is this the reversal?

User Image Bwnuts Posted - 5 days ago

$IMRX if the pattern holds true, this is the pump before the Powell dump.

User Image intratio Posted - 5 days ago

$IMRX https://www.intratio.com/stock-forecast/IMRX The network concludes that this company s stock price has a good setup for the short-term with a seriously optimistic longer-term setup

User Image sportymn11 Posted - 04/30/24

$IMRX what was up with that pump to $1.58? Positive sign?

User Image Car_key Posted - 04/30/24

$IMRX Insider bought bunch of share above this price.

User Image Car_key Posted - 04/30/24

$IMRX Do not worry, it will fly like Cotton.

User Image Leekangghoun Posted - 04/30/24

$IMRX buying some stock with tsla profit

User Image intratio Posted - 04/30/24

Immuneering Corp The trained A.I judges the stock price of this company will increase soon with a seriously optimistic longer-term setup $IMRX

User Image HuntingBenjmins Posted - 04/29/24

$IMRX We’ll that just fell off like a rock!

User Image FrankieBee Posted - 04/29/24

$IMRX ok...wtf happened just after 3??? goddamn....

User Image biff1 Posted - 04/29/24

$IMRX

User Image intratio Posted - 04/27/24

$IMRX https://www.intratio.com/stock-forecast/IMRX The AI is making the inference this company s value has a nice setup for the immediate future with a seriously optimistic longer-term setup

User Image Bwnuts Posted - 04/25/24

$IMRX same pattern tomorrow just slot in 1.30 for 1.40.

User Image Scientific_Swings Posted - 04/25/24

$IMRX Adding more to our position

User Image clemsoncrew Posted - 04/25/24

$IMRX I checked the recent SEC filings. I do not see anything of concern with those. No splits nor offerings that I can see coming. Just a proxy vote for directors in June. I think they must start announcing press releases soon. They had a lot in March but very little in April. That should get some interest once they start announcing news.

User Image FrankieBee Posted - 04/25/24

$IMRX ...and the freefall continues. wtf.

User Image bobwut12 Posted - 04/25/24

$IMRX Does anyone here have a list of any potential catalysts coming out over the next couple of months? I tried looking into it myself but couldn't find any so any help would be greatly appreciated

User Image sportymn11 Posted - 04/24/24

$IMRX I don’t understand the all time low for this stock was $3.70 before this last drop and Analysts have a price target of $15.00. It make no sense why it keeps dropping. This is ridiculous

User Image Bwnuts Posted - 04/24/24

$IMRX strong possibility they are in the process of repricing options so all employees don’t walk out the door in this strong jobs market. If this is the case, the company doesn’t want the stock price going up either. In this case they let it drop and do nothing to stop it.

User Image Bwnuts Posted - 04/24/24

$IMRX $1.20 tomorrow. No reason it's not going there.

User Image Bwnuts Posted - 04/24/24

$IMRX I think we close at 1.20

User Image sportymn11 Posted - 04/24/24

$IMRX what the heck. I just don’t understand what’s going on this is Way over sold. Should be at $3 minimum IMO

Analyst Ratings
Needham Buy Apr 12, 24
Mizuho Buy Apr 2, 24
Jefferies Hold Mar 15, 24
Chardan Capital Buy Mar 15, 24
Needham Buy Mar 15, 24
TD Cowen Market Perform Mar 15, 24
Guggenheim Neutral Mar 14, 24
Needham Buy Mar 11, 24
Oppenheimer Outperform Mar 5, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Zeskind Benjamin J. PRESIDENT AND CEO PRESIDENT AND CEO Dec 22 Option 3.01 2,500 7,525 2,261,852 12/27/22
Bookman Michael GENERAL COUNSEL AND.. GENERAL COUNSEL AND SECRETARY May 17 Buy 4.88 1,000 4,880 2,402 05/18/22
KEATING LAURIE Director Director May 16 Buy 5 7,000 35,000 14,000 05/17/22
Amin Biren CFO, TREASURER CFO, TREASURER May 12 Buy 4.42 1,000 4,420 7,898 05/12/22
Zeskind Benjamin J. PRESIDENT AND CEO PRESIDENT AND CEO Apr 12 Option 3.01 2,000 6,020 2,259,352 04/14/22
Zeskind Benjamin J. PRESIDENT AND CEO PRESIDENT AND CEO Mar 23 Buy 8.02 3,000 24,060 2,257,352 03/24/22
Hall Brett Matthew CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Mar 23 Buy 7.91 1,050 8,306 330,134 03/23/22
Barrett Scott CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER Mar 22 Buy 7.485 900 6,736 7,563 03/22/22
Feinberg Peter Director Director Mar 15 Buy 6.75 6,667 45,002 11,766 03/16/22
BERMAN ANN E Director Director Mar 15 Buy 6.40 6,000 38,400 9,500 03/15/22
Zeskind Benjamin J. PRESIDENT AND CEO PRESIDENT AND CEO Feb 28 Option 3.01 2,000 6,020 2,254,352 03/01/22